WO2013039295A1 - 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 - Google Patents
신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 Download PDFInfo
- Publication number
- WO2013039295A1 WO2013039295A1 PCT/KR2012/006441 KR2012006441W WO2013039295A1 WO 2013039295 A1 WO2013039295 A1 WO 2013039295A1 KR 2012006441 W KR2012006441 W KR 2012006441W WO 2013039295 A1 WO2013039295 A1 WO 2013039295A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alpha
- antitrypsin
- variant
- leu
- lys
- Prior art date
Links
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title claims abstract description 273
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title claims abstract description 272
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title claims abstract description 271
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims abstract description 35
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 230000013595 glycosylation Effects 0.000 claims description 53
- 238000006206 glycosylation reaction Methods 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 235000018102 proteins Nutrition 0.000 claims description 38
- 230000004927 fusion Effects 0.000 claims description 33
- 229940024606 amino acid Drugs 0.000 claims description 32
- 235000001014 amino acid Nutrition 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 21
- 229960001230 asparagine Drugs 0.000 claims description 21
- 235000009582 asparagine Nutrition 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 13
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 8
- 239000002753 trypsin inhibitor Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 101710081722 Antitrypsin Proteins 0.000 claims description 5
- 230000001475 anti-trypsic effect Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 21
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 17
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 17
- 230000004988 N-glycosylation Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 9
- 210000004102 animal cell Anatomy 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000035772 mutation Effects 0.000 abstract description 3
- 239000013598 vector Substances 0.000 description 29
- 230000002441 reversible effect Effects 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 23
- 102000051631 human SERPINA1 Human genes 0.000 description 18
- 210000003714 granulocyte Anatomy 0.000 description 17
- 102000018997 Growth Hormone Human genes 0.000 description 15
- 108010051696 Growth Hormone Proteins 0.000 description 15
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 15
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 15
- 239000000122 growth hormone Substances 0.000 description 15
- 229910052698 phosphorus Inorganic materials 0.000 description 15
- 239000011574 phosphorus Substances 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 12
- 239000008055 phosphate buffer solution Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 6
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 108010025306 histidylleucine Proteins 0.000 description 6
- 108010017391 lysylvaline Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000006167 equilibration buffer Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- FVSOUJZKYWEFOB-KBIXCLLPSA-N Ala-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N FVSOUJZKYWEFOB-KBIXCLLPSA-N 0.000 description 3
- LTSBJNNXPBBNDT-HGNGGELXSA-N Ala-His-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)O LTSBJNNXPBBNDT-HGNGGELXSA-N 0.000 description 3
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 3
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 3
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 3
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 3
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 3
- YFHATWYGAAXQCF-JYJNAYRXSA-N Arg-Pro-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YFHATWYGAAXQCF-JYJNAYRXSA-N 0.000 description 3
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 3
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 3
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 3
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 3
- PHJPKNUWWHRAOC-PEFMBERDSA-N Asn-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PHJPKNUWWHRAOC-PEFMBERDSA-N 0.000 description 3
- XLZCLJRGGMBKLR-PCBIJLKTSA-N Asn-Ile-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XLZCLJRGGMBKLR-PCBIJLKTSA-N 0.000 description 3
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 3
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 3
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 3
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 3
- BKXPJCBEHWFSTF-ACZMJKKPSA-N Asp-Gln-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O BKXPJCBEHWFSTF-ACZMJKKPSA-N 0.000 description 3
- VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 3
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 3
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 3
- GWWSUMLEWKQHLR-NUMRIWBASA-N Asp-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GWWSUMLEWKQHLR-NUMRIWBASA-N 0.000 description 3
- XAPPCWUWHNWCPQ-PBCZWWQYSA-N Asp-Thr-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XAPPCWUWHNWCPQ-PBCZWWQYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 3
- NSNUZSPSADIMJQ-WDSKDSINSA-N Gln-Gly-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NSNUZSPSADIMJQ-WDSKDSINSA-N 0.000 description 3
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 3
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 3
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 3
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 3
- IRDASPPCLZIERZ-XHNCKOQMSA-N Glu-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N IRDASPPCLZIERZ-XHNCKOQMSA-N 0.000 description 3
- QPRZKNOOOBWXSU-CIUDSAMLSA-N Glu-Asp-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N QPRZKNOOOBWXSU-CIUDSAMLSA-N 0.000 description 3
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 3
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 3
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 3
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 3
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 3
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 3
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 3
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 3
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 3
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 3
- QGDOOCIPHSSADO-STQMWFEESA-N Gly-Met-Phe Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGDOOCIPHSSADO-STQMWFEESA-N 0.000 description 3
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 3
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- ZJSMFRTVYSLKQU-DJFWLOJKSA-N His-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ZJSMFRTVYSLKQU-DJFWLOJKSA-N 0.000 description 3
- QSLKWWDKIXMWJV-SRVKXCTJSA-N His-Cys-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N QSLKWWDKIXMWJV-SRVKXCTJSA-N 0.000 description 3
- AKEDPWJFQULLPE-IUCAKERBSA-N His-Glu-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O AKEDPWJFQULLPE-IUCAKERBSA-N 0.000 description 3
- OWYIDJCNRWRSJY-QTKMDUPCSA-N His-Pro-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O OWYIDJCNRWRSJY-QTKMDUPCSA-N 0.000 description 3
- KDDKJKKQODQQBR-NHCYSSNCSA-N His-Val-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N KDDKJKKQODQQBR-NHCYSSNCSA-N 0.000 description 3
- HZMLFETXHFHGBB-UGYAYLCHSA-N Ile-Asn-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZMLFETXHFHGBB-UGYAYLCHSA-N 0.000 description 3
- UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 3
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 3
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 3
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 3
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 3
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 3
- RFUBXQQFJFGJFV-GUBZILKMSA-N Leu-Asn-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RFUBXQQFJFGJFV-GUBZILKMSA-N 0.000 description 3
- BOFAFKVZQUMTID-AVGNSLFASA-N Leu-Gln-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N BOFAFKVZQUMTID-AVGNSLFASA-N 0.000 description 3
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 3
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 3
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 3
- IBSGMIPRBMPMHE-IHRRRGAJSA-N Leu-Met-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O IBSGMIPRBMPMHE-IHRRRGAJSA-N 0.000 description 3
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 3
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 3
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 3
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 3
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 3
- PYFNONMJYNJENN-AVGNSLFASA-N Lys-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PYFNONMJYNJENN-AVGNSLFASA-N 0.000 description 3
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 3
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 3
- XGZDDOKIHSYHTO-SZMVWBNQSA-N Lys-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 XGZDDOKIHSYHTO-SZMVWBNQSA-N 0.000 description 3
- JACAKCWAOHKQBV-UWVGGRQHSA-N Met-Gly-Lys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN JACAKCWAOHKQBV-UWVGGRQHSA-N 0.000 description 3
- BEZJTLKUMFMITF-AVGNSLFASA-N Met-Lys-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCNC(N)=N BEZJTLKUMFMITF-AVGNSLFASA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- JNRFYJZCMHHGMH-UBHSHLNASA-N Phe-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JNRFYJZCMHHGMH-UBHSHLNASA-N 0.000 description 3
- LBSARGIQACMGDF-WBAXXEDZSA-N Phe-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 LBSARGIQACMGDF-WBAXXEDZSA-N 0.000 description 3
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 3
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 description 3
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 3
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 3
- AUJWXNGCAQWLEI-KBPBESRZSA-N Phe-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AUJWXNGCAQWLEI-KBPBESRZSA-N 0.000 description 3
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 3
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 3
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 3
- XYAFCOJKICBRDU-JYJNAYRXSA-N Pro-Phe-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O XYAFCOJKICBRDU-JYJNAYRXSA-N 0.000 description 3
- HRIXMVRZRGFKNQ-HJGDQZAQSA-N Pro-Thr-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HRIXMVRZRGFKNQ-HJGDQZAQSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 3
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 3
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 3
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 3
- IUXGJEIKJBYKOO-SRVKXCTJSA-N Ser-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N IUXGJEIKJBYKOO-SRVKXCTJSA-N 0.000 description 3
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 3
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 3
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 3
- HAUVENOGHPECML-BPUTZDHNSA-N Ser-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 HAUVENOGHPECML-BPUTZDHNSA-N 0.000 description 3
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 3
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 3
- QNCFWHZVRNXAKW-OEAJRASXSA-N Thr-Lys-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QNCFWHZVRNXAKW-OEAJRASXSA-N 0.000 description 3
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 description 3
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 3
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 3
- SPIFGZFZMVLPHN-UNQGMJICSA-N Thr-Val-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SPIFGZFZMVLPHN-UNQGMJICSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- AZZLDIDWPZLCCW-ZEWNOJEFSA-N Tyr-Ile-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O AZZLDIDWPZLCCW-ZEWNOJEFSA-N 0.000 description 3
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 3
- QGFPYRPIUXBYGR-YDHLFZDLSA-N Val-Asn-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N QGFPYRPIUXBYGR-YDHLFZDLSA-N 0.000 description 3
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 3
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 3
- CHWRZUGUMAMTFC-IHRRRGAJSA-N Val-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CNC=N1 CHWRZUGUMAMTFC-IHRRRGAJSA-N 0.000 description 3
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 3
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 3
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 3
- WANVRBAZGSICCP-SRVKXCTJSA-N Val-Pro-Met Chemical compound CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C)C(O)=O WANVRBAZGSICCP-SRVKXCTJSA-N 0.000 description 3
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 3
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 3
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 108010077245 asparaginyl-proline Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010085059 glutamyl-arginyl-proline Proteins 0.000 description 3
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 3
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 3
- 108010081551 glycylphenylalanine Proteins 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 3
- 108010053037 kyotorphin Proteins 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 108010085203 methionylmethionine Proteins 0.000 description 3
- 108010068488 methionylphenylalanine Proteins 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 108010024607 phenylalanylalanine Proteins 0.000 description 3
- 108010012581 phenylalanylglutamate Proteins 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 108010025488 pinealon Proteins 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- 108010073969 valyllysine Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 101000823102 Bos taurus Alpha-1-antiproteinase Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004471 Glycine Chemical group 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- CZWANIQKACCEKW-CYDGBPFRSA-N Ile-Pro-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)O)N CZWANIQKACCEKW-CYDGBPFRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003602 elastase inhibitor Substances 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 102200075245 rs118204104 Human genes 0.000 description 2
- 102220094401 rs749548566 Human genes 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- GVUGADOWXGKRAE-SRVKXCTJSA-N 4-[[(2s)-1-[[(2s)-1-[[(2s)-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GVUGADOWXGKRAE-SRVKXCTJSA-N 0.000 description 1
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- IPYVXYDYLHVWHU-GMOBBJLQSA-N Ile-Asn-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N IPYVXYDYLHVWHU-GMOBBJLQSA-N 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940038528 aralast Drugs 0.000 description 1
- 150000001507 asparagine derivatives Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940099982 prolastin Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940032528 zemaira Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to novel alpha-1 antitrypsin variants, methods for their preparation and uses.
- Alpha-1 antitrypsin is one of the proteins present in the blood of mammals with a molecular weight of about 50,000 Daltons consisting of 394 amino acids, and its concentration in blood is one of the main blood proteins of about 2 mg / mL ( Robin WC et. Al ., Nature, 298, 329-334, 1982), also called alpha-1 protease inhibitors.
- Alpha-1 antitrypsin has more than 100 alleles in nature, and phenotypes are classified from A to Z according to the type of isoelectric focusing (IEF). Most of the M-type alleles are present in the blood of most people, with at least about 75 isoforms known to be present (Brantley, M. et. Al ., Am. J. Med., 84 (suppl. 6A). ), 13-31, 1988), the main function as a protease inhibitor is also maintained.
- IEF isoelectric focusing
- alpha-1 antitrypsin In general, about 90% of alpha-1 antitrypsin is known to have five PiM subtypes of M1, M2, M3, M4 and M5. Among them, M1 is about 67%, M2 is about 16%, and M3 is about 11% (Cox D. W. & Billingsley D. G., FEBS Lett., 231, 327-330, 1986). Among the M2 type, His exists at position 101 and Arg exists at position 101, and it is known that it does not affect the intrinsic activity of alpha-1 antitrypsin.
- Alpha-1 antitrypsin has the structure of glycoproteins that are commonly glycosylated in three of the proteins (Mega, T. et. Al ., J. Biol. Chem., 255, 4057-4061, 1980), X According to the ray crystal structure, alpha-1 antitrypsin, like other protease inhibitors in the blood (Serpins), has three beta-sheets and eight alpha-helical structures. (Elliot PR, et. Al ., JMB, 275, 419-425, 1988).
- Alpha-1 antitrypsin inhibits various types of proteolytic enzymes in the body, and the main function in vivo associated with currently known diseases is by inhibiting the activity of neutrophil elastase (Beatty et. Al ., J. Biol. Chem., 255, 3931-3934, 1980), deficiency of alpha-1 antitrypsin causes severe diseases such as emphysema, which results in decreased lung function due to the breakdown of elastin.
- the modified protein of alpha-1 antitrypsin is not properly secreted by the liver, and the modified alpha-1 antitrypsin accumulates in the liver, resulting in cirrhosis.
- Typical products include Tlastcris Prolastin, Baxter Aralast, and CSL Behring Zemaira, which are typically administered at 60 mg / kg intravenously at weekly intervals. Administered. Therefore, large amounts of 4-5 g of protein per week per adult should be administered to the patient for a long time.
- Human alpha-1 antitrypsin is known to have three N-glycans due to glycosylation at a total of three sites (46 asparagine, 83 asparagine, and 247 asparagine).
- Alpha-1 antitrypsin produced by microorganisms such as E. coli by genetic recombination method is not glycosylated, unlike human-derived alpha-1 antitrypsin, and has a short half-life when administered in vivo (Karnaukhova et. . al., Amino Acids, 30 , 317-332, 2006, Garver Jr. et. al., Proc.. Nati. Acad. Sci. USA, 84, 1050-1054, 1987).
- alpha-1 antitrypsin In order to overcome this problem and economically obtain a large amount of alpha-1 antitrypsin, studies have been conducted to express alpha-1 antitrypsin in plants. However, although plant-derived glycosylation occurred in recombinant alpha-1 antitrypsin expressed in plants, the half-life in the body was reported to be shorter than that of human alpha-1 antitrypsin (Huang et. Al. , Biotechnol. Prog., 17, 126-133, 2001).
- Alpha-1 antitrypsin from animal cells is known to have a half-life in vivo similar to human alpha-1 antitrypsin (Garver Jr. et. Al ., Proc. Nati. Acad. Sci. USA., 84, 1050-1054). , 1987). Therefore, it can be said that it is a preferable method to manufacture using animal cells similar in sugar structure to human alpha-1 antitrypsin.
- a production method using animal cells has a disadvantage in that manufacturing costs are generally higher than that of producing alpha-1 antitrypsin using microorganisms.
- the inventors have prepared alpha-1 antitrypsin variants by adding glycosylation to several specific sites of alpha-1 antitrypsin in order to construct clinically useful recombinant alpha-1 antitrypsin, and half-life in blood (t 1/2 ).
- the area under the drug concentration-time curve (AUC) was significantly increased to identify the alpha-1 antitrypsin variant having excellent body stability and maintaining the inhibitory effect of elastase.
- the present invention provides an alpha-1 antitrypsin variant wherein a glycosylation site is added by substituting an amino acid at a specific site between positions 1 to 25 of the N-terminus of alpha-1 antitrypsin.
- the alpha-1 antitrypsin variant is characterized in that the addition of one to three glycosylation sites.
- the specific site is characterized in that it is located between positions 3 to 13 of the N-terminus.
- the specific site is characterized in that the 9 or 12 position of the N-terminal.
- the specific site is characterized in that the position 4 and 9, or 4 and 12, or 9 and 12 of the N-terminal.
- the present invention comprises the steps of adding a glycosylation site by substituting an amino acid at a specific site between positions 1 to 25 of the N-terminus of alpha-1 antitrypsin; Culturing the cells transfected with the alpha-1 antitrypsin variant expression vector to which the glycosylation site is added on a culture medium; Expressing alpha-1 antitrypsin variant protein from said cells; And it provides a method for producing an alpha-1 antitrypsin variant comprising the step of purifying and recovering the expressed alpha-1 antitrypsin variant protein.
- the present invention is an alpha-1 antitrypsin mutant containing an amino acid at a specific site between the 1 and 25 positions of the N-terminal of alpha-1 antitrypsin to add a glycosylation site as an active ingredient, alpha -1
- a composition for preventing or treating antitrypsin deficiency is provided.
- the alpha-1 antitrypsin deficiency is characterized by chronic obstructive pulmonary disease or cirrhosis.
- the present invention is administered to the patient in a therapeutically effective amount of the alpha-1 antitrypsin mutant having a glycosylation site added by replacing the amino acid at a specific site between the 1 and 25 positions of the alpha-1 antitrypsin
- a method for preventing or treating alpha-1 antitrypsin deficiency is provided.
- the present invention connects two alpha-1 antitrypsin variants in which a glycosylation site is added by substituting an amino acid at a specific site between positions 1 to 25 of the N-terminus of alpha-1 antitrypsin, and thus the half-life of the body is A fusion of increased alpha-1 antitrypsin variants.
- the present invention is heterologous by connecting another heterologous protein to the alpha-1 antitrypsin variant in which the glycosylation site is added by substituting an amino acid at a specific site between positions 1 to 25 of the N-terminal of alpha-1 antitrypsin.
- the glycosylation site is added by substituting an amino acid at a specific site between positions 1 to 25 of the N-terminal of alpha-1 antitrypsin.
- the alpha-1 antitrypsin variant is further characterized in that the proline, which is the 357th amino acid at the P2 position, is substituted with asparagine.
- Alpha-1 antitrypsin variant according to the present invention adds an N-glycosylation site through amino acid variation between positions 1 to 25 at the N-terminus, thereby reducing blood half-life (t 1/2 ) and drug concentration-time curve
- the lower area (AUC) is significantly increased, so the stability in the body is excellent, and the effect of inhibiting elastase activity is maintained. Therefore, the alpha-1 antitrypsin variant of the present invention can be usefully used for the prevention or treatment of alpha-1 antitrypsin deficiency. It can also be used to increase the half-life of the heterologous protein by binding the heterologous protein to the alpha-1 antitrypsin variant according to the present invention.
- 1 is a schematic diagram of the alpha-1 antitrypsin vector (pT003) of the present invention.
- FIG. 2 is a diagram showing the sequence and position of the alpha-1 antitrypsin variant of the present invention.
- Figure 3 is a diagram showing the SDS-PAGE results of the purified alpha-1 antitrypsin and variants thereof of the present invention.
- FIG. 4 is a diagram showing a subcutaneous administration pharmacokinetic graph of plasma-derived alpha-1 antitrypsin and recombinant alpha-1 antitrypsin expressed in animal cells of the present invention.
- FIG. 5 is a diagram showing a subcutaneous administration pharmacokinetic graph of alpha-1 antitrypsin and variants thereof of the present invention.
- Figure 6 is a diagram showing the subcutaneous administration pharmacokinetics graph of plasma-derived alpha-1 antitrypsin, recombinant alpha-1 antitrypsin variants.
- Figure 7 is a diagram showing the subcutaneous and intravenous administration pharmacokinetic graph of the alpha-1 antitrypsin variants of the present invention.
- FIG. 8 is a graph showing intravenous pharmacokinetic graphs of alpha-1 antitrypsin and dimer of the present invention.
- FIG. 9 is a diagram showing a subcutaneous administration pharmacokinetic graph of the fusion of the phosphorus growth hormone / alpha-1 antitrypsin variant of the present invention.
- FIG. 10 is a diagram showing a subcutaneous administration pharmacokinetic graph of the granulocyte stimulator / alpha-1 antitrypsin variant fusion of the present invention.
- the present invention provides an alpha-1 antitrypsin variant in which a glycosylation site is added by substituting an amino acid at a specific site between positions 1 to 25 of the N-terminus of alpha-1 antitrypsin.
- Alpha-1 antitrypsin variants according to the present invention are located between positions 1 to 25 at the N-terminus in addition to the three glycosylation sites of alpha-1 antitrypsin (46 asparagine, 83 asparagine, 247 asparagine)
- the N-glycosylation site is added by substituting amino acids at specific sites.
- an N-glycosylation site to a specific site of the N-terminal of the human alpha-1 antitrypsin may include the Asn-X-Thr, which is an N-glycan attachment site sequence between positions 1 to 25 of the N-terminal Create / Ser.
- the glycosylation site is substituted by asparagine with glutamine, an amino acid at positions 3 to 13 of the N-terminus of human alpha-1 antitrypsin, most preferably at positions 9 or 12 of the N-terminus.
- Add The variant by glycosylation may obtain a structure in which sugars are simultaneously added to positions 4 and 9, 4 and 12, or 9 and 12, and the N-terminus in addition to the specific region described in this embodiment. It may also include additional glycosylation at other sites within 25 of.
- the present invention is to replace the amino acid at a specific site between the position 1 to 25 of the N- terminal of alpha-1 antitrypsin to add a glycosylation site, the alpha-1 antitrypsin to which the glycosylation site is added Culturing the cells transfected with the variant expression vector on a culture medium, expressing the alpha-1 antitrypsin variant protein from the culture medium; And it provides a method for producing an alpha-1 antitrypsin variant comprising the step of purifying and recovering the expressed alpha-1 antitrypsin variant protein.
- N-glycosylation site uses genetic recombination technology, and the N-glycosylation site may be added by substitution, insertion and removal of amino acids through genetic engineering.
- N-terminal about 20 amino acids of the human alpha-1 antitrypsin are poorly detected in the X-ray crystal structure of alpha-1 antitrypsin (PDB code: 1QLP, 2QUG, 3CWL, 1PSI, 7API, 1KCT ( www.pdb.org )) has a tertiary structure that is not very flexible.
- Alpha-1 antitrypsin variants according to the invention can be prepared by mutating one or more amino acids using a site-directed mutagenesis method. For example, in human alpha-1 antitrypsin, when glutamine at position 9 is replaced with asparagine or glycine at position 148 with asparagine and expressed in animal cells, glycosylation sites are generated in the substituted asparagine. Alternatively, replacing 148 glycine with threonine creates a new glycosylation site in 146 asparagine. In this way, glycosylation sites can be added at a wide variety of positions of alpha-1 antitrypsin.
- the N-terminal 1 which does not show a structure in the X-ray crystal structure of A1AT Alpha-1 antitrypsin variants were prepared by adding N-glycosylation sites through substitution of amino acids at specific sites between positions 25 and 25, which were then expressed in Chinese Hamster Ovary cells and chromatographed. Obtained by high purity using the method.
- the alpha-1 antitrypsin variant to which the purified N-glycosylation site was added shows a staining band at a relatively high position in the SDS-PAGE test compared to wild type alpha-1 antitrypsin. It is judged that the molecular weight rose due to glycation.
- the purified alpha-1 antitrypsin variant has an excellent stability in the body by significantly increasing the area under the curve (AUC) value and half-life (t 1/2 ) in the blood.
- AUC area under the curve
- t 1/2 half-life
- the persistence in the body was not improved by the addition of the N-glycosylation site, and the loop region described in WO 2008/151845 A, loop B, loop C, loop D, loop E) or alpha-1 antitrypsin mutant with a glycosylation site in the vicinity did not have a significant effect on improving the sustainability.
- glycosylation of the loop region may affect the activity of alpha-1 antitrypsin, which has a unique function as a protease, and thus the selection of glycosylation sites that do not affect the activity of alpha-1 antitrypsin. very important.
- the purified alpha-1 antitrypsin variant was confirmed to maintain the inhibitory effect of elastase activity.
- the binding rate constant of human alpha-1 antitrypsin is generally 1.0 ⁇ 0.2 ⁇ 10 5 (Boudier C., 1994) to 1.67 ⁇ 10 6 M ⁇ 1 s ⁇ 1 (Terashima M, et. Al. , Appl. Microbiol.Biotechnol., 52 (4), 516-523, 1999), wherein the binding rate constants and equilibrium constants of the wild-type human alpha-1 antitrypsin of the present invention and variants thereof are similar.
- glycosylation of the N-terminal region of alpha-1 antitrypsin does not affect the inhibition of elastase activity of alpha-1 antitrypsin.
- the present invention also provides a fusion of alpha-1 antitrypsin variants with increased half-life in the body by linking the two alpha-1 antitrypsin variants.
- the present inventors prepared an alpha-1 antitrypsin double variant in which proline, which is the 357th amino acid of the P2 position of the alpha-1 antitrypsin variant, was further substituted with asparagine, and a fusion conjugated with the granulocyte stimulating factor was prepared.
- proline which is the 357th amino acid of the P2 position of the alpha-1 antitrypsin variant
- asparagine asparagine
- the present invention provides a fusion of alpha-1 antitrypsin variants with increased half-life of the heterologous proteins by linking other heterologous proteins to the alpha-1 antitrypsin variants.
- the heterologous protein is preferably a bioactive peptide or a bioactive protein.
- the purified alpha-1 antitrypsin variant can be linked to two or more to prepare a fusion of alpha-1 antitrypsin variant with increased half-life in the body.
- Sytkowski, AJ, et al. Found that erythrocyte growth factor (EPO) was transformed into a fusion protein of EPO-EPO using an appropriate linker, resulting in significantly increased activity and an increase in body half-life than EPO monomers.
- EPO erythrocyte growth factor
- alpha-1 antitrypsin variants of the present invention when two or more alpha-1 antitrypsin variants of the present invention are linked, it is expected that the half-life of the body will be increased compared to the monomer of the alpha-1 antitrypsin variant. Furthermore, when the alpha-1 antitrypsin variant of the present invention is linked to a biologically active peptide, an immunomodulator, a cytokine, etc. having a short half-life in the body, the half-life in the body is significantly increased, and thus, it is expected to exhibit a long-lasting effect.
- the present invention also provides a composition for the prevention or treatment of alpha-1 antitrypsin deficiency containing the alpha-1 antitrypsin variant as an active ingredient.
- the present invention also provides a method of preventing or treating alpha-1 antitrypsin deficiency by administering to the patient a therapeutically effective amount of alpha-1 antitrypsin variant.
- the alpha-1 antitrypsin variant according to the present invention adds an N-glycosylation site through amino acid variation between positions 1 to 25 at the N-terminus, thereby reducing blood half-life (t1 / 2) and The area under the drug concentration-time curve (AUC) is significantly increased, so that the stability in the body is excellent and the inhibitory effect of elastase activity is maintained. Therefore, the alpha-1 antitrypsin variant of the present invention can be usefully used for the prevention or treatment of alpha-1 antitrypsin deficiency.
- the alpha-1 antitrypsin deficiency includes chronic obstructive pulmonary disease (COPD) or cirrhosis, and preferably includes but is not limited to emphysema.
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- cirrhosis preferably includes but is not limited to emphysema.
- composition of the present invention may contain one or more known active ingredients having a prophylactic or therapeutic effect of alpha-1 antitrypsin deficiency together with alpha-1 antitrypsin variant.
- composition of the present invention can be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration.
- Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added.
- Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
- composition of the present invention may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally, inhaled or topically) according to the desired method, or the alpha-1 antitrypsin variant according to the present invention. It can be used for Gene Therapy. Dosage varies depending on the weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of the patient.
- the weekly dose of the alpha-1 antitrypsin variant is equivalent to less than 60 mg / kg of the alpha-1 antitrypsin dose, or equivalent dose, or the same dose as the wild type alpha-1 antitrypsin dose. If used, it is expected that the same clinical efficacy will be achieved even with longer administration periods.
- composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, drug treatment and biological response modifiers for the prevention or treatment of alpha-1 antitrypsin deficiency.
- the expression vector cloning required for the present invention used pSGHV0 (GenBank Accession No. AF285183), which is a parent vector, and used a pAV1 vector that was improved and developed for use in industry.
- the parental vector expresses a human-derived protein using a bacterium such as E. coli, the protein is overexpressed in the cell, but most of them are not active. Because it has the properties to make, it is a research vector produced for the purpose of easily purifying the protein with physiological activity.
- the one of the biggest advantages of pSGHV0 vector, which has high expression level has been modified to be used in industry to use in production.
- an alpha-1 antitrypsin vector (pT003) was prepared by cloning an alpha-1 antitrypsin (M3) gene with hMU001448 (KRIBB) into a pAV1 vector.
- M3 alpha-1 antitrypsin
- KRIBB alpha-1 antitrypsin
- two primers XhoAT forward primer (5'-CCC TCC TCG AGA ATG CCG TCT TCT GTC TCG-3 ', SEQ ID NO: 1) and ATNot reverse primer (5'-GGG) were used as templates for hMU001448 (KRIBB).
- PCR was amplified using CCC GCG GCC GCA GTT ATT TTT GGG TGG G-3 ', SEQ ID NO: 2).
- the amplified nucleotides were cleaved with two restriction enzymes, XhoI and NotI, present at the ends, and conjugated with an expression vector pAV1 having an XhoI / NotI cleavage to prepare an alpha-1 antitrypsin vector (pT003, SEQ ID NO: 39).
- pT003 A schematic diagram of the alpha-1 antitrypsin vector (pT003) is shown in FIG. 1.
- alpha-1 antitrypsin variants In order to prepare several alpha-1 antitrypsin variants to which glycosylation sites were added, each of the two forward primers described in Table 1 using the alpha-1 antitrypsin vector (pT003) prepared in Example 1-2 as a template Alpha-1 antitrypsin variants were prepared using reverse primers and variant generation kit (Enzynomix, EZchangeTM Site-Directed Mutagenesis Kit). The sequence and position of the alpha-1 antitrypsin variant are shown in FIG. 2.
- an alpha-1 antitrypsin gene with pEAT8 (encoding a1-AT (M2) cDNA) as a template was cloned into a pAV1 vector to prepare an alpha-1 antitrypsin vector (pT006).
- XhoAT forward primers (5'-CCC TCC TCG AGA ATG CCG TCT TCT GTC TCG-3 ', SEQ ID NO: 1) and ATNot using pEAT8 (encoding a1-AT (M2) cDNA) as a template PCR was amplified using reverse primers (5′-GGG CCC GCG GCC GCA GTT ATT TTT GGG TGG G-3 ′, SEQ ID NO: 2).
- the amplified nucleotides were cleaved with two restriction enzymes, XhoI and NotI, present at the ends, and conjugated with an expression vector pAV1 having an XhoI / NotI cleavage to prepare an alpha-1 antitrypsin vector (pT006, SEQ ID NO: 40). .
- alpha-1 antitrypsin (M2) variant to which the glycosylation site was added, the following two primers were prepared using the alpha-1 antitrypsin vector (pT006) prepared in Example 1-4 as a template.
- Alpha-1 antitrypsin (M2) variant vector (AT9N (M2)) was prepared using a variant generation kit (Enzynomix, EZchangeTM Site-Directed Mutagenesis Kit) using 5) and a reverse primer (SEQ ID NO: 6).
- SEQ ID NO: 42 The amino acid sequence of the prepared alpha-1 antitrypsin variant is shown in SEQ ID NO: 42.
- alpha-1 antitrypsin variants used pAT9N (subtype M2).
- XhoAT forward primer 2 5'-GGG CCC CTC GAG GCC ACC ATG CCG TCT TCT GTC TCG TGG GGC ATC CTC CTG CTG GCA GGC CTG TGC TGC
- M2 pAT9N
- ATBam reverse primer 2 (5'-GGG GGG ATC CTC TTT TTG GGT GGG ATT CAC -3', SEQ ID NO: 32) Amplification by PCR.
- the amplified nucleotide was cleaved with two restriction enzymes, XhoI and BamHI, present at the terminal, and conjugated with an expression vector pAT9N (M2) having an XhoI / BamHI cleavage region to produce an alpha-1 antitrypsin duplex vector (pAT9N (M2)).
- pAT9N (M2) was prepared.
- alpha-1 antitrypsin T003, T006
- CHO-K1 Chinese hamster ovary cells
- DMEM Dulbecco's Modified Eagle Media
- FBS Fetal Bovine Serum
- the expression vectors of the variants and duplexes thereof were mixed and maintained at room temperature for 1 minute, followed by mixing with 20 ⁇ g of PEI (Polyethylenimine, linear, Polysciences Inc. (Cat. No: 23966, MW ⁇ 25,000)). It was left at room temperature for 15 minutes. At this time, cells cultured one day ago were washed with PBS, and 6 mL of DMEM was added thereto. After 10 to 15 minutes, each of the expression vectors of alpha-1 antitrypsin and its variants and duplexes which were left at room temperature was added to the culture dish. The next day, washed with PBS and the protein expression was confirmed by the addition of IMBS (Cat. No 12200-028, Gibco, Iscove's Modified Dulbecco's Medium) medium without FBS.
- IMBS Cat. No 12200-028, Gibco, Iscove's Modified Dulbecco's Medium
- Alpha-1 antitrypsin expressed in Example 1-7 and its variants and duplexes were purified as follows. Specifically, in order to purify the alpha-1 antitrypsin and its variants and duplexes secreted into the cell culture, the culture medium is centrifuged to remove the cells, and then only the supernatant is taken and the cell supernatant is equilibrated with a buffer solution (20 mM sodium phosphate, pH 8.0). Dilution).
- the cell supernatant diluted with the equilibration buffer was injected into the Q-Sepharose (GE Healthcare, USA) column equilibrated with the equilibration buffer, washed well with the equilibration buffer, and the concentration of sodium chloride was increased (0 to 400 mM NaCl). , 20 mM sodium phosphate, pH 8.0) to elute the protein.
- the eluted protein is injected into an Alpha-1 Antitrypsin Select (GE Healthcare, USA) column equilibrated with equilibration buffer (Tris 50 mM, sodium chloride 0.15M, pH 7.5), washed thoroughly with equilibration buffer and the concentration of MgCl 2 increased. Protein was eluted.
- Alpha-1 antitrypsin variant was used as pAT9N (subtype M2) to prepare a fusion of phosphorus growth hormone / alpha-1 antitrypsin variant (AT9N).
- XhoGH forward primer (5'-GGG CCC CTC GAG GCC ACC ATG GCT ACA GGC TCC CGG-3 ', SEQ ID NO: 33) were used as a template for phosphorus growth hormone gene (IOH45734 (invitrogen)).
- GHBam reverse primer 5'-GGG GGG ATC CTC GAA GCC ACA GCT GCC CTC-3 ', SEQ ID NO: 34).
- the amplified nucleotides were cleaved with two restriction enzymes, XhoI and BamHI, and conjugated with an expression vector pAT9N (M2) having an XhoI / BamHI cleavage chain to form a phosphorus growth hormone / alpha-1 antitrypsin variant fusion vector ( phGH-AT9N (M2), SEQ ID NO: 43) was prepared.
- alpha-1 antitrypsin variant (AT9N) vector prepared in the same manner as in Example 1-5, the following two primers forward primers (5'-CCA TGT TTT TAG AGG CCA TAA ACA TGT CTA TCC CCC CC-3) ', SEQ ID NO: 35) and reverse primer (5'-GGG GGG GAT AGA CAT GTT TAT GGC CTC TAA AAA CAT GG-3', SEQ ID NO: 36) and variant generation kit (Enzynomix, EZchangeTM Site-Directed Mutagenesis Kit) Glutamin at position 9 at alpha-1 antitrypsin N-terminus is replaced with asparagine, and proline at position 357 is replaced with asparagine.
- Vector pT004N (Q9N, P357N) containing variants was prepared.
- the amino acid sequence of the prepared alpha-1 antitrypsin bivariate is shown in SEQ ID NO: 44.
- pT004N (Q9N, P357N) comprising alpha-1 antitrypsin bivariate prepared by the method of Example 3-1 was used.
- XhoCSF forward primer (5'-GGG CCC CTC GAG ATG GCT GGA CCT GCC ACC-3), were prepared using granulocyte colony stimulating factor (IHS1380-97652343 (Open biosystems)) as a template.
- CSFBam reverse primers (5'-GGG GGG ATC CTC GGG CTG GGC AAG GTG GCG-3', SEQ ID NO: 38) were amplified by PCR.
- the amplified nucleotides were cleaved with two restriction enzymes, XhoI and BamHI, and conjugated with an expression vector pT004N having an XhoI / BamHI cleavage to obtain granulocyte stimulator / alpha-1 antitrypsin bivariate fusion vector (pT603N, SEQ ID NO: 45) was prepared. Then, using the prepared vector (pT603N) was expressed and purified granulocyte stimulator / alpha-1 antitrypsin bivariate in the same manner as in Examples 1-7 and 1-8.
- Sprague-Dawley male rats were used as experimental animals, and 3 to 5 animals were allocated to each experimental group.
- Sprague-Dawley rats in each group were injected subcutaneously or intravenously with plasma-derived human alpha-1 antitrypsin (Calbiochem, USA), recombinant alpha-1 antitrypsin and variants thereof at a dose of 445 ⁇ g per kg rat, respectively.
- Phosphate buffer solution was used. After administration, blood was collected by centrifugation and serum was obtained. Serum obtained at each blood collection time was stored frozen until analysis, and blood concentrations of alpha-1 antitrypsin and its variants were measured using enzyme immunoassay. Enzyme immunoassay was performed in two ways. The first method is as follows.
- Monoclonal antibodies against human alpha-1 antitrypsin (Medix Biochemica, Finland) were coated onto plates (Nunc, Denmark) and treated with phosphate buffer in which 1% bovine serum albumin was dissolved. The samples were diluted with phosphate buffer containing 1% bovine serum albumin, and alpha-1 antitrypsin monoclonal antibody-biotin conjugate and streptavidin conjugated using sulfo-NHS-biotin (Pierce biotechnology, USA). Alpha-1 antitrypsin was detected using -HRP. The color reaction was performed using TMB (3,3 ', 5,5'-tetramethylbenzidine) and hydrogen peroxide coloring solution.
- TMB 3,3 ', 5,5'-tetramethylbenzidine
- the second method was a monoclonal antibody against human alpha-1 antitrypsin (Medix Biochemica, Finland) coated on a plate (Nunc, Denmark) and treated with phosphate buffer in 1% bovine serum albumin. Samples were diluted with phosphate buffer containing 1% bovine serum albumin, and alpha-1 antitrypsin using alpha-1 antitrypsin polyclonal antibody-biotin conjugate (Abcam, UK) and streptavidin-HRP. Detected.
- the color reaction was performed using TMB (3,3 ', 5,5'-tetramethylbenzidine) and hydrogen peroxide coloring solution. After adding sulfuric acid to each well to terminate the reaction, 450nm with a microplate reader (Molecular Device, USA). Absorbance was measured at. Plates were washed with wash solution (0.05% Tween 20, phosphate buffer) at each stage. Quantitative values of each sample were obtained by regression analysis after preparing a standard curve for the standard.
- Subcutaneous administration pharmacokinetic graphs and intravenous administration pharmacokinetic graphs of alpha-1 antitrypsin derived from plasma-derived alpha-1 antitrypsin and Chinese hamster ovary cells and variants thereof are shown in FIGS. 4, 5, 6 and 7, respectively. .
- plasma-derived alpha-1 antitrypsin, recombinant alpha-1 antitrypsin and its variants showed various pharmacokinetics upon subcutaneous administration.
- the plasma-derived alpha-1 antitrypsin showed a half-life (t 1/2 ) in the body of about 15.2 hours, a Tmax of 16.8 hours, and an AUC (hr * ⁇ g / mL) value of 113.1.
- 1 Antitrypsin (T003) had a half-life (t 1/2 ) of about 16.5 hours, a Tmax of 20.8 hours, and an AUC (hr * ⁇ g / mL) value of 156.6 hours.
- alpha-1 antitrypsin prepared from Chinese hamster ovary cells was not significantly different from plasma-derived alpha-1 antitrypsin, and recombinant alpha-1 antitrypsin had a half-life (t 1 / t) compared to plasma-derived alpha-1 antitrypsin. 2 ) and Tmax were slightly longer, and AUC (hr * ⁇ g / mL) was increased by about 40%.
- M2 type (His101) and M3 type (Arg101), which are isoforms of alpha-1 antitrypsin showed no difference within the test error range in animal pharmacokinetic tests.
- variants of alpha-1 antitrypsin prepared in Chinese hamster ovary cells showed various pharmacokinetic patterns depending on the glycosylation site added.
- AT70N, AT178N, AT201N, and AT212N showed AUCINF_obs (hr * ⁇ g / mL) as low as about 50-70% of alpha-1 antitrypsin (T003) prepared in Chinese hamster ovary cells.
- alpha-1 antitrypsin T003
- the variants were about 15-90% longer than wild-type alpha-1 antitrypsin prepared in Chinese hamster ovary cells, indicating that the addition of glycosylation site influenced the half-life of the body.
- AUC (hr * ⁇ g / mL) was similar to that of alpha-1 antitrypsin prepared in Chinese hamster ovary cells, but the half-life of the body increased by about 50% to 24.6 hours. This indicates that the pharmacokinetic pattern was improved by adding the glycosylation site of AT148T.
- the half-life of AT26T is slightly longer than alpha-1 antitrypsin (T003) prepared in Chinese hamster ovary cells, whereas AUC (hr * ⁇ g / mL) is alpha-1 antitrypsin prepared in Chinese hamster ovary cells. It is only about 17% of (T003), and the excretion rate (CL / F; mL / hr / kg) is about 6 times higher, so adding the glycosylation site at position 26 is the worst in terms of pharmacokinetics. Indicated.
- FIG. 6 shows pharmacokinetic graphs upon subcutaneous administration of plasma-derived alpha-1 antitrypsin and recombinant alpha-1 antitrypsin variants.
- Plasma-derived alpha-1 antitrypsin had a half-life (t 1/2 ) of about 15.2 hours
- AT148T had a half-life of 24.6 hours
- AT9N of 37.7 hours
- AT212N of 19.1 hours.
- Various aspects were shown depending on the added glycosylation site.
- alpha-1 antitrypsin mutants (AT26T, AT148T, AT178N, AT201N, AT212N), in which the loop region of alpha-1 antitrypsin was mutated for additional glycosylation, did not further glycosylate. Although there was a slight increase in half-life compared to -1 antitrypsin, other pharmacokinetics showed inferior results than wild type recombinant alpha-1 antitrypsin (T003), which resulted in clinically wild type alpha- 1 There is no superiority to antitrypsin.
- glycosylation site at the N-terminus 9 of the variants further glycosylated with recombinant alpha-1 antitrypsin significantly improves body persistence as well as significantly lowers body excretion compared to other sugar-added variants. Able to know. Therefore, we examined whether pharmacokinetic parameters change when sugar is added at the position below amino acid 25 of the N-terminal peptide structure of alpha-1 antitrypsin.
- FIG. 7 shows the results of pharmacokinetic experiments of variants glycosylated at the N-terminal 4, 9 and 12 positions of alpha-1 antitrypsin.
- AUC area under the curve
- Association rate constant (ka) was calculated using the activity of porcine pancreatic elastase remaining at each reaction time, and the results are shown in Table 2.
- Ka (M -1 ) [EI] / [E] f / [I] f ⁇ 10 9
- the binding rate constants and equilibrium constants of wild type human alpha-1 antitrypsin (T003) and the variant of alpha-1 antitrypsin AT9N are the binding rate constants of plasma-derived human alpha-1 antitrypsin. And values similar to the equilibrium constants.
- T003 and the variant of alpha-1 antitrypsin AT9N are the binding rate constants of plasma-derived human alpha-1 antitrypsin.
- AT148T affects the half-life of the body due to the addition of glycosylation
- sugar added at position 148 of alpha-1 antitrypsin affects the binding of alpha-1 antitrypsin and proteolytic enzyme. It can be seen that.
- Variants such as AT70N and AT178N also showed significantly lower binding capacity than wild-type plasma-derived alpha-1 antitrypsin in binding to elastase. This suggests that adding glycosylation at specific positions of alpha-1 antitrypsin may affect the pharmacokinetics of the body, but selection of glycosylation sites that do not affect the activity of alpha-1 antitrypsin is very important.
- Sprague-Dawley rats were used as experimental animals, and three mice were assigned to the phosphorus growth hormone administration group and five to the fusion administration group.
- Sprague-Dawley rats were injected subcutaneously with a phosphorus growth hormone / alpha-1 antitrypsin fusion prepared in Example 2 at a dose of 720 ⁇ g per kg of rat, respectively, and dilutions were used with phosphate buffer solution, 0, 1, 2 , 4, 8, 12, 16, 24, 30, 48 hours after the blood was collected to obtain a serum after centrifugation.
- Scitropin (SciGen, Singapore), a phosphorus growth hormone, was injected subcutaneously at a dose of 200 ⁇ g / kg, and a diluent was used as a phosphate buffer solution, and 0, 0.33, 1, 2, 5, 8, 12, 18 After 24, 30 and 48 hours, blood was collected and centrifuged to obtain serum. Each sample was analyzed using the following enzyme immunoassay method. Monoclonal antibodies against phosphorus growth hormone (Medix Biochemica, Finland) were diluted in phosphate buffer at a concentration of 1-5 ⁇ g / mL, and 100 ⁇ L was dispensed into 96-well plates (Nunc, Denmark) for 15-18 hours at room temperature. It was left.
- phosphate buffer solution in which 1% bovine serum albumin was dissolved was dispensed and left at room temperature for 2 hours, and washed three times with a washing solution (0.05% Tween 20, phosphate buffer solution). The solution was then removed. Samples were diluted with phosphate buffer solution in which 1% bovine serum albumin was dissolved, and added to a 96-well plate and reacted at room temperature for 2 hours.
- the phosphorus growth hormone monoclonal antibody-biotin conjugate conjugated using sulfo-NHS-biotin (Pierce biotechnology, USA) was diluted in diluent solution and 100 ⁇ L was dispensed into the 96-well plate. . Subsequently, the plate was allowed to react at room temperature for 2 hours, and then washed 5 times with a washing solution, and then streptavidin-HRP solution was added and reacted at room temperature for 30 minutes.
- TMB 3,3 ', 5,5'-tetramethylbenzidine
- hydrogen peroxide coloring solution was added to each well and allowed to react in the dark for 30 minutes.
- 100 ⁇ L of 1 M sulfuric acid was added to each well to terminate the reaction, and the absorbance was measured at 450 nm with a VersaMax microplate reader (Molecular Device, USA). Quantitative values of each sample were obtained by regression analysis after preparing a standard curve for the standard.
- the pharmacokinetic graph of the fusion of phosphorus growth hormone / alpha-1 antitrypsin variant according to the present invention is shown in FIG. 9.
- the blood half-life (t 1/2 ) of the fusion of the phosphorus growth hormone / alpha-1 antitrypsin variant of the present invention is about 6 hours, which is 4 times higher than that of the phosphorus growth hormone. It was confirmed that it has.
- Sprague-Dawley rats were used as experimental animals. Five mice were assigned to the granulocyte stimulator-administered group and three mice to the fusion-administered group. Sprague-Dawley rats were injected subcutaneously with granulocyte stimulating factor / alpha-1 antitrypsin bivariate fusion (pT603N) prepared by the method of Example 3 at a dose of 340 ⁇ g / kg of rat, respectively, and as a diluent phosphate buffer solution (phosphate).
- pT603N granulocyte stimulating factor / alpha-1 antitrypsin bivariate fusion
- PBS buffered saline
- granulocyte stimulator Grasine Grasin, Filgrastim
- ELISA enzyme immunoassay method
- Monoclonal antibodies against granulocyte stimulating factors were diluted in a phosphate buffer solution at a concentration of 1-10 ⁇ g / mL, and 100 ⁇ L were dispensed into 96-well plates (Nunc, Denmark) and left at room temperature for 15-18 hours. Then, after removing the remaining antibody that is not attached to the well plate, disperse 250 ⁇ L of phosphate buffer solution in which 1% bovine serum albumin is dissolved, and leave it at room temperature for 2 hours and wash it with washing solution (0.05% Tween 20, phosphate buffer solution) three times. The solution was then removed.
- Samples were diluted with phosphate buffer solution in which 1% bovine serum albumin was dissolved, and added to a 96-well plate and reacted at room temperature for 2 hours. After washing the 96 well plate five times with the washing solution, the granulocyte stimulator polyclonal antibody-biotin conjugate (R & D systems) was diluted in the diluent solution and 100 ⁇ L was dispensed into the 96 well plate. Subsequently, the plate was allowed to react at room temperature for 2 hours, and then washed 5 times with a washing solution. Streptavidin-HRP solution was added thereto for 30 minutes at room temperature, followed by washing 5 times with washing solution and TMB (3,3 ', 5,5).
- phosphate buffer solution in which 1% bovine serum albumin was dissolved
- the blood half-life (t 1/2 ) of the granulocyte stimulator / alpha-1 antitrypsin bivariate fusion of the present invention is about 7.3 hours, which is about 3 times higher than that of 2.7 hours of granulocyte stimulator, and AUC is It was confirmed that the body stability was significantly increased more than three times. Through the above results, it was confirmed that the binding of heterologous proteins such as bioactive proteins to the alpha-1 antitrypsin double variant can increase the half-life of the heterologous protein.
- the alpha-1 antitrypsin variant in which the N-glycosylation site is added through amino acid mutations between the 1 and 25 positions of the N-terminus of the present invention, is used for the prevention or treatment of alpha-1 antitrypsin deficiency
- the half-life (t 1/2 ) and the area under the drug concentration-time curve (AUC) are significantly increased, so that the stability in the body is excellent and the inhibitory effect of elastase activity is maintained. Therefore, the use of the alpha-1 antitrypsin variant according to the present invention can be used for alpha-1 antitrypsin deficiency, and can be used to bind the heterologous protein to the alpha-1 antitrypsin variant to increase the half-life of the heterologous protein. It can be usefully used as a therapeutic agent.
- cagcacctgg aaaatgaact cacccacgat atcatcacca agttcctgga aaatgaagac 840
- cagcacctgg aaaatgaact cacccacgat atcatcacca agttcctgga aaatgaagac 840
- cagcactgta agaagctgtc cagctgggtg ctgctgatga aatacctggg caatgccacc 1320
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
Description
프라이머 | 서열 |
Q4N-F(서열번호 3) | 5'-AAC GGA ACT GCT GCC CAG AAG ACA GAT ACA-3' |
Q4N-R(서열번호 4) | 5'-GGG ATC CTC AGC CAG GGA GAC-3' |
Q9N-F(서열번호 5) | 5'-AAC AAG ACA GAT ACA TCC CAC-3' |
Q9N-R(서열번호 6) | 5'-GGC AGC ATC TCC CTG GGG ATC-3' |
D12N-F(서열번호 7) | 5'-AAT ACA ACC CAC CAT GAT CAG GAT CAC-3' |
D12N-R(서열번호 8) | 5'-TGT CTT CTG GGC AGC ATC TCC-3' |
I26T-F(서열번호 9) | 5'-ACT ACC CCC AA CCT GGC TG-3' |
I26T-R(서열번호 10) | 5'-CTT GTT GAA GGT TGG GTG ATC C-3' |
A31T-F(서열번호 11) | 5'-ACT GAG TTC GCC TTC AGC CTA TAC-3' |
A31T-R(서열번호 12) | 5'-CAG GTT GGG GGT GAT CTT GTT G-3' |
L66N-F(서열번호 13) | 5'-AAC GGG ACC AAG GCT GAC AC-3' |
L66N-R(서열번호 14) | 5'-GGA GAG CAT TGC AAA GGC TGT A-3' |
A70N-F(서열번호 15) | 5'-AAC GAC ACT CAC GAT GAA ATC CTG-3' |
A70N-R(서열번호 16) | 5'-CTT GGT CCC CAG GGA GAG-3' |
G148N-F(서열번호 17) | 5'-AAC GAC ACC GAA GAG GCC AAG-3' |
G148N-R(서열번호 18) | 5'-GAA GTT GAC AGT GAA GGC TTC TG-3' |
G148T-F(서열번호 19) | 5'-ACT GAC ACC GAA GAG GCC AAG-3' |
G148T-R(서열번호 20) | 5'-GAA GTT GAC AGT GAA GGC TTC TG-3' |
R178N-F(서열번호 21) | 5'-AAC GAC ACA GTT TTT GCT CTG GTG-3' |
R178N-R(서열번호 22) | 5'-GTC AAG CTC CTT GAC CAA ATC CA-3' |
K201N-F(서열번호 23) | 5'-AAC GAC ACC GAG GAA GAG GAC-3' |
K201N-R(서열번호 24) | 5'-GAC TTC AAA GGG TCT CTC CCA TT-3' |
Q212N-F(서열번호 25) | 5'-AAC GTG ACC ACC GTG AAG GTG-3' |
Q212N-R(서열번호 26) | 5'-GTC CAC GTG GAA GTC CTC TTC-3' |
E266N-F(서열번호 27) | 5'-AAC CTC ACC CAC GAT ATC ATC AC-3' |
E266N-R(서열번호 28) | 5'-ATT TTC CAG GTG CTG TAG TTT CCC-3' |
K343N-F(서열번호 29) | 5'-AAC GGG ACT GAA GCT G-3' |
K343N-R(서열번호 30) | 5'-CTC GTC GAT GGT CAG C-3' |
엘라스타제 억제제 | 결합 속도상수(ka (M-1s-1)) |
혈장 알파-1 안티트립신 | 5.4×105 |
T003 | 6.5×105 |
AT9N | 6.0×105 |
엘라스타 억제제 | 평형상수(Ka(M-1)) |
혈장 알파-1 안티트립신 | 2.60×109 |
T003 | 3.56×109 |
AT9N | 3.04×109 |
Claims (12)
- 알파-1 안티트립신의 N-말단의 1번 위치에서 25번 위치 사이의 특정 부위에 있는 아미노산을 치환하여 당화 부위를 추가시킨, 알파-1 안티트립신 변이체.
- 제 1 항에 있어서,상기 알파-1 안티트립신 변이체는 당화 부위를 하나 내지 세 개 이하로 추가시킨 것을 특징으로 하는, 알파-1 안티트립신 변이체.
- 제 1 항에 있어서,상기 특정 부위는 N-말단의 3번 위치에서 13번 위치 사이인 것을 특징으로 하는, 알파-1 안티트립신 변이체.
- 제 1 항에 있어서,상기 특정 부위는 N-말단의 9번 혹은 12번 위치인 것을 특징으로 하는, 알파-1 안티트립신 변이체.
- 제 1 항에 있어서,상기 특정 부위는 N-말단의 4번과 9번, 혹은 4번과 12번, 혹은 9번과 12번 위치인 것을 특징으로 하는, 알파-1 안티트립신 변이체.
- a) 알파-1 안티트립신의 N-말단의 1번 위치에서 25번 위치 사이의 특정 부위에 있는 아미노산을 치환하여 당화 부위를 추가시키는 단계;b) 상기 당화 부위가 추가된 알파-1 안티트립신 발현벡터를 전이시킨 세포를 배양 배지 상에서 배양하는 단계;c) 상기 세포로부터 알파-1 안티트립신 변이체 단백질을 발현시키는 단계; 및d) 상기 발현된 알파-1 안티트립신 변이체 단백질을 정제하고 회수하는 단계를 포함하는, 알파-1 안티트립신 변이체의 제조방법.
- 알파-1 안티트립신의 N-말단의 1번 위치에서 25번 위치 사이의 특정 부위에 있는 아미노산을 치환하여 당화 부위를 추가시킨 알파-1 안티트립신 변이체를 유효성분으로 함유하는, 알파-1 안티트립신 결핍증의 예방 또는 치료용 조성물.
- 제 7 항에 있어서,상기 알파-1 안티트립신 결핍증은 만성 폐쇄성 폐질환 혹은 간경변인 것을 특징으로 하는, 조성물.
- 알파-1 안티트립신의 N-말단의 1번 위치에서 25번 위치 사이의 특정 부위에 있는 아미노산을 치환하여 당화 부위를 추가시킨 알파-1 안티트립신 변이체를 치료적 유효량으로 환자에게 투여하는 것을 특징으로 하는, 알파-1 안티트립신 결핍증의 예방 또는 치료방법.
- 알파-1 안티트립신의 N-말단의 1번 위치에서 25번 위치 사이의 특정 부위에 있는 아미노산을 치환하여 당화 부위를 추가시킨 알파-1 안티트립신 변이체 두 개를 연결하여 체내 반감기가 증가된 알파-1 안티트립신 변이체의 융합체.
- 알파-1 안티트립신의 N-말단의 1번 위치에서 25번 위치 사이의 특정 부위에 있는 아미노산을 치환하여 당화 부위를 추가시킨 알파-1 안티트립신 변이체에 다른 이종 단백질을 연결하여 이종 단백질의 체내 반감기가 증가된 알파-1 안티트립신 변이체의 융합체.
- 제 11 항에 있어서,상기 알파-1 안티트립신 변이체는 추가적으로 P2 위치인 357번째 아미노산인 프롤린(proline)이 아스파라진(asparagine)으로 치환된 것을 특징으로 하는, 알파-1 안티트립신 변이체의 융합체.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012309292A AU2012309292B2 (en) | 2011-09-15 | 2012-08-13 | Novel alpha 1-antitrypsin variant, preparation method thereof, and use thereof |
CA2848919A CA2848919C (en) | 2011-09-15 | 2012-08-13 | Novel alpha 1-antitrypsin variant, preparation method thereof and use thereof |
BR112014005788-5A BR112014005788B1 (pt) | 2011-09-15 | 2012-08-13 | variante de antitrispsina alfa-1, método de preparação da mesma, composição farmacêutica compreendendo a mesma fusão de variante de antitrispsina alfa-1 |
JP2014530581A JP6001074B2 (ja) | 2011-09-15 | 2012-08-13 | 新規なα−1アンチトリプシン変異体、その製造方法及び用途 |
MX2014003183A MX349364B (es) | 2011-09-15 | 2012-08-13 | Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma. |
RU2014114790/10A RU2567007C1 (ru) | 2011-09-15 | 2012-08-13 | Новый вариант альфа-1-антитрипсина, способ его получения и применения |
US14/344,468 US9051395B2 (en) | 2011-09-15 | 2012-08-13 | Alpha-1 antitrypsin variant, preparation method thereof and use thereof |
EP12831806.0A EP2757110B1 (en) | 2011-09-15 | 2012-08-13 | Novel alpha 1-antitrypsin variant, preparation method thereof, and use thereof |
CN201280044912.8A CN103827141B (zh) | 2011-09-15 | 2012-08-13 | 新型α-1抗胰蛋白酶变体及其制备方法和用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110092819 | 2011-09-15 | ||
KR10-2011-0092819 | 2011-09-15 | ||
KR10-2012-0058998 | 2012-06-01 | ||
KR1020120058998A KR101402702B1 (ko) | 2011-09-15 | 2012-06-01 | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013039295A1 true WO2013039295A1 (ko) | 2013-03-21 |
Family
ID=48179554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/006441 WO2013039295A1 (ko) | 2011-09-15 | 2012-08-13 | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9051395B2 (ko) |
EP (1) | EP2757110B1 (ko) |
JP (1) | JP6001074B2 (ko) |
KR (1) | KR101402702B1 (ko) |
CN (1) | CN103827141B (ko) |
AU (1) | AU2012309292B2 (ko) |
BR (1) | BR112014005788B1 (ko) |
CA (1) | CA2848919C (ko) |
MX (1) | MX349364B (ko) |
RU (1) | RU2567007C1 (ko) |
WO (1) | WO2013039295A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6231559B2 (ja) | 2012-06-05 | 2017-11-15 | シージェイ ヘルスケア コーポレイションCj Healthcare Corporation | 高グリコシル化された持続型ヒト成長ホルモンタンパク質の製造方法及び精製方法 |
WO2019125002A1 (ko) | 2017-12-20 | 2019-06-27 | (주)알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
KR102167827B1 (ko) * | 2017-12-20 | 2020-10-20 | 주식회사 알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
WO2019237079A2 (en) * | 2018-06-07 | 2019-12-12 | Xiaolong Zhang | Pharmaceutical composition containing fusion protein and use thereof |
KR102134571B1 (ko) * | 2018-06-15 | 2020-07-16 | 주식회사 알테오젠 | 혈액응고인자 VII/VIIa 융합단백질의 제조 방법 |
CN113286586A (zh) | 2018-06-22 | 2021-08-20 | Ucl商业有限公司 | 新化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0133252B1 (ko) * | 1993-05-18 | 1998-04-14 | 김은영 | 내열성의 알파-1-안티트립신 뮤테인 |
WO2008151845A2 (en) | 2007-06-15 | 2008-12-18 | Charite - Universitätsmedizin Berlin | Methods for producing glycosylated human alpha-1 antitrypsin (a1at) in mammalian host cells |
WO2010123290A2 (ko) * | 2009-04-22 | 2010-10-28 | (주)알테오젠 | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0701570B1 (en) * | 1993-05-18 | 2001-12-19 | Korea Institute Of Science And Technology | Thermoresistant alpha-1-antitrypsin mutein |
RU2392963C2 (ru) * | 2004-08-09 | 2010-06-27 | Элиоз Байофарма, Инк. | Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов |
JP6231559B2 (ja) * | 2012-06-05 | 2017-11-15 | シージェイ ヘルスケア コーポレイションCj Healthcare Corporation | 高グリコシル化された持続型ヒト成長ホルモンタンパク質の製造方法及び精製方法 |
-
2012
- 2012-06-01 KR KR1020120058998A patent/KR101402702B1/ko active IP Right Grant
- 2012-08-13 AU AU2012309292A patent/AU2012309292B2/en active Active
- 2012-08-13 CN CN201280044912.8A patent/CN103827141B/zh active Active
- 2012-08-13 JP JP2014530581A patent/JP6001074B2/ja active Active
- 2012-08-13 MX MX2014003183A patent/MX349364B/es active IP Right Grant
- 2012-08-13 RU RU2014114790/10A patent/RU2567007C1/ru active
- 2012-08-13 CA CA2848919A patent/CA2848919C/en active Active
- 2012-08-13 BR BR112014005788-5A patent/BR112014005788B1/pt active IP Right Grant
- 2012-08-13 EP EP12831806.0A patent/EP2757110B1/en active Active
- 2012-08-13 US US14/344,468 patent/US9051395B2/en active Active
- 2012-08-13 WO PCT/KR2012/006441 patent/WO2013039295A1/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0133252B1 (ko) * | 1993-05-18 | 1998-04-14 | 김은영 | 내열성의 알파-1-안티트립신 뮤테인 |
WO2008151845A2 (en) | 2007-06-15 | 2008-12-18 | Charite - Universitätsmedizin Berlin | Methods for producing glycosylated human alpha-1 antitrypsin (a1at) in mammalian host cells |
WO2010123290A2 (ko) * | 2009-04-22 | 2010-10-28 | (주)알테오젠 | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 |
Non-Patent Citations (20)
Title |
---|
"Remington's Pharmaceutical Science", MACK PUBLISHING COMPANY |
BEATTY, J. BIOL. CHEM., vol. 255, 1980, pages 3931 - 3934 |
BLANCHARD ET AL.: "N-glycosylation and biological activity of recombinant human alphal-antitrypsin expressed in a novel human neuronal cell line", BIOTECHNOLOGY AND BIOENGINEERING, vol. 108, no. 9, 14 April 2011 (2011-04-14), pages 2118 - 2128, XP055148374 * |
BRANTLEY, M., AM. J. MED., vol. 84, no. 6A, 1988, pages 13 - 31 |
CANTIN, AM. J. RESPIR. CELL. MOL. BIOL., vol. 27, 2002, pages 659 - 665 |
COMUNALE ET AL.: "Linkage specific fucosylation of alpha-1-antitrypsin in livercirrhosis and cancer patients: implications for a biomarker Df hepatocellular carcinoma", PLOS ONE, vol. 5, 25 August 2010 (2010-08-25), pages 1 - 9, XP055148373 * |
COX D.W.; BILLINGSLEY D.G., FEBS LETT., vol. 231, 1986, pages 327 - 330 |
ELIOTT, NAT. BIOTECHNOL., vol. 21, 2003, pages 414 - 421 |
ELLIOT P.R., JMB, vol. 275, 1988, pages 419 - 425 |
GARVER ET AL.: "''Production of glycosylated physiologically ''normal'''' human alphal-antitrypsin by mouse fibroblasts modified by insertion of a human alphal-antitrypsin cDNA using a retroviral vector''", PNAS, vol. 84, 1987, pages 1050 - 1054, XP002540833 * |
GARVER JR., PROC. NATL. ACAD. SCI. USA., vol. 84, 1987, pages 1050 - 1054 |
HUANG, BIOTECHNOL. PROG., vol. 17, 2001, pages 126 - 133 |
KARNAUKHOVA, AMINO ACIDS, vol. 30, 2006, pages 317 - 332 |
LEVENSPIEL O.: "Chemical reaction engineering", 1972, WILEY |
MEGA, T., J. BIOL. CHEM., vol. 255, 1980, pages 4057 - 4061 |
MILLS ET AL.: "The underglycosylation of plasma alpha 1-antitrypsin in congenital disorders of glycosylation type I is not random", GLYCOBIOLOGY, vol. 13, no. 2, 2003, pages 73 - 85, XP055148375 * |
ROBIN W.C., NATURE, vol. 298, 1982, pages 329 - 334 |
See also references of EP2757110A4 |
SYTKOWSKI, A.J., J. BIOL. CHEM., vol. 274, 1999, pages 24773 - 24778 |
TERASHIMA M, APPL. MICROBIOL. BIOTECHNOL., vol. 52, no. 4, 1999, pages 516 - 523 |
Also Published As
Publication number | Publication date |
---|---|
JP2014534166A (ja) | 2014-12-18 |
EP2757110A1 (en) | 2014-07-23 |
KR101402702B1 (ko) | 2014-06-05 |
AU2012309292A1 (en) | 2014-04-24 |
EP2757110B1 (en) | 2017-09-27 |
CA2848919A1 (en) | 2013-03-21 |
MX349364B (es) | 2017-07-26 |
CA2848919C (en) | 2016-09-13 |
BR112014005788B1 (pt) | 2021-01-12 |
RU2567007C1 (ru) | 2015-10-27 |
CN103827141B (zh) | 2016-01-13 |
BR112014005788A2 (pt) | 2017-03-28 |
MX2014003183A (es) | 2015-01-12 |
RU2014114790A (ru) | 2015-10-20 |
EP2757110A4 (en) | 2015-04-22 |
KR20130029713A (ko) | 2013-03-25 |
AU2012309292B2 (en) | 2015-05-07 |
US20140371160A1 (en) | 2014-12-18 |
JP6001074B2 (ja) | 2016-10-05 |
CN103827141A (zh) | 2014-05-28 |
US9051395B2 (en) | 2015-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013039295A1 (ko) | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 | |
WO2010123290A2 (ko) | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 | |
WO2017116205A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
WO2018004283A2 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
WO2017116207A1 (ko) | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 | |
WO2019066586A1 (ko) | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 | |
WO2020130749A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 | |
WO2022139493A1 (ko) | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 | |
WO2022015082A1 (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
WO2021066600A1 (ko) | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 | |
WO2022015115A1 (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 | |
WO2020071865A1 (ko) | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 | |
WO2023106845A1 (ko) | 신규한 아디포넥틴 아날로그 및 결합체 | |
WO2022035200A1 (ko) | Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2022119380A1 (ko) | 신규한 ace2 변이체 및 그의 이용 | |
WO2020263063A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도 | |
WO2020242268A1 (ko) | 비오틴 모이어티와 결합된 생리활성 물질 및 이를 포함하는 경구 투여용 조성물 | |
WO2017010790A1 (ko) | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 | |
WO2022080991A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도 | |
WO2011111914A1 (ko) | 합토글로빈 유전자가 도입된 혈관내피 전구세포 및 이를 포함하는 혈관형성 촉진용 조성물 | |
WO2022216129A1 (ko) | 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물 | |
WO2023059160A1 (ko) | 섬유증의 예방 또는 치료용 융합 단백질 | |
WO2022035302A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 | |
WO2021235907A1 (ko) | 글루카곤 유도체의 지속형 결합체의 액상 제제 | |
WO2023277620A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12831806 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14344468 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2848919 Country of ref document: CA Ref document number: 2014530581 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/003183 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2012831806 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012831806 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014114790 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012309292 Country of ref document: AU Date of ref document: 20120813 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005788 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005788 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140313 |